Holen Sie sich die Stockscreener-App
24.63
1.99%
-0.50
Schlusskurs vom Vortag:
$25.13
Offen:
$25.58
24-Stunden-Volumen:
4.06M
Relative Volume:
2.71
Marktkapitalisierung:
$2.17B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.78M
KGV:
-11.96
EPS:
-2.0595
Netto-Cashflow:
$-136.42M
1W Leistung:
+2.88%
1M Leistung:
-6.67%
6M Leistung:
-33.43%
1J Leistung:
+79.39%
1-Tages-Spanne:
$24.52
$25.99
1-Wochen-Bereich:
$23.26
$25.99
52-Wochen-Spanne:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
24.63 | 2.17B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | TD Cowen | Buy |
| 2025-06-11 | Eingeleitet | Jefferies | Hold |
| 2024-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Mineralys Therapeutics Inc (MLYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mineralys Therapeutics Inc (MLYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey
Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor - Seeking Alpha
Mineralys Therapeutics Inc (MLYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics director Karydas sells $75,000 in stock By Investing.com - Investing.com India
Mineralys Therapeutics (MLYS) CMO sells 14,474 shares, exercises options - Stock Titan
Director at Mineralys Therapeutics (MLYS) trades 3,000 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics CMO Rodman sells $350,086 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics director Karydas sells $75,000 in stock - Investing.com
Mineralys Therapeutics CMO Rodman sells $350,086 in stock - Investing.com
Mineralys Therapeutics Inc (MLYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mineralys Therapeutics (NASDAQ: MLYS) files Form 144 to sell 4,584 shares - Stock Titan
Mineralys Therapeutics (MLYS) Rule 144: 3,000-share cashless exercise - Stock Titan
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock - Yahoo Finance UK
The Technical Signals Behind (MLYS) That Institutions Follow - Stock Traders Daily
Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise - Stock Titan
Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis - Quiver Quantitative
Mineralys Therapeutics Presents Late-Breaking Data on - GlobeNewswire
Mineralys Therapeutics (MLYS) CMO sells 8,519 shares after option exercises - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) files Rule 144 disclosing 6,349‑share cashless exercise - Stock Titan
Akin, an Elite Global Law Firm - Akin
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat - Insider Monkey
Transcript : Mineralys Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering - Global Legal Chronicle
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
MLYS: Lorundrostat advances toward launch with strong clinical data, strategic deals, and broad payer support - TradingView
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Biopharma Mineralys joins Goldman Sachs health-care talks in Miami - Stock Titan
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - The Manila Times
Mineralys Therapeutics to Present Late-Breaking Data on - GlobeNewswire
Latham Advises Mineralys Therapeutics in Unique Three-Pronged Transaction — Royalty Repurchase, Debt Financing, and Equity Offering — Totaling Up to US$950 Million - Legal Desire Media and Insights
Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data - Yahoo Finance
Mineralys Therapeutics Stock In Shambles: Down -25% With 6-Day Losing Streak - Trefis
Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak - Trefis
Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones - Stock Traders Daily
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Insider Monkey
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Mineralys Therapeutics prices $150M stock offering - MSN
Latham Advises Mineralys Therapeutics in Unique Three-Pronged - Latham & Watkins LLP
Mineralys pays up to $300 million to clear lorundrostat royalties - The Pharma Letter
MLYS Stock Sees 17.1% Decline Amid Market Movements - GuruFocus
Mineralys announces $150 million equity offering and financing - TipRanks
Mineralys (Nasdaq: MLYS) prices $150M stock sale to fund $200M royalty buyback - Stock Titan
Mineralys (MLYS) raises ~$150M in $26.50/share offering to fund royalty repurchase - Stock Titan
Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty Obligations - Moomoo
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):